Personalis (NASDAQ:PSNL) Shares Down 4.4% – Time to Sell?

Personalis, Inc. (NASDAQ:PSNL)’s share price fell 4.4% on Wednesday . The company traded as low as $10.78 and last traded at $10.72. 239,827 shares traded hands during trading, a decline of 79% from the average session volume of 1,122,262 shares. The stock had previously closed at $11.21.

Analyst Upgrades and Downgrades

PSNL has been the topic of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a report on Wednesday, October 8th. Needham & Company LLC lifted their price objective on shares of Personalis from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Guggenheim upped their price objective on shares of Personalis from $6.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. HC Wainwright raised their target price on shares of Personalis from $8.50 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Finally, Lake Street Capital reiterated a “buy” rating and set a $11.00 price target on shares of Personalis in a research note on Wednesday, November 5th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $10.29.

Personalis Stock Down 4.5%

The company has a market cap of $951.05 million, a PE ratio of -12.18 and a beta of 1.92. The stock’s 50 day simple moving average is $8.09 and its two-hundred day simple moving average is $6.46.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. The firm had revenue of $14.50 million during the quarter, compared to the consensus estimate of $13.31 million. Personalis had a negative return on equity of 38.25% and a negative net margin of 106.92%. Personalis has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Analysts forecast that Personalis, Inc. will post -1.4 EPS for the current year.

Insider Transactions at Personalis

In related news, CEO Christopher M. Hall sold 29,612 shares of the stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $8.99, for a total transaction of $266,211.88. Following the completion of the sale, the chief executive officer owned 148,486 shares of the company’s stock, valued at approximately $1,334,889.14. This represents a 16.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 3.80% of the company’s stock.

Institutional Investors Weigh In On Personalis

Institutional investors have recently bought and sold shares of the business. Legal & General Group Plc purchased a new position in shares of Personalis in the 2nd quarter valued at $30,000. Ameritas Investment Partners Inc. purchased a new stake in Personalis during the 2nd quarter worth $34,000. BNP Paribas Financial Markets increased its holdings in Personalis by 406.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after purchasing an additional 5,177 shares in the last quarter. Focus Partners Wealth purchased a new position in Personalis in the first quarter valued at about $47,000. Finally, Alpha Wealth Funds LLC purchased a new position in Personalis in the second quarter valued at about $66,000. 61.91% of the stock is currently owned by hedge funds and other institutional investors.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.